Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Melanotan II crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence102 certificate records mentioning this compound or product name46 provider-linked · 84 exact product matches

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Dermal / cosmetic research

Primary research area: Dermal. Also surfaces under Hormone for browsing and discovery.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Low

No FDA label signal · 1 trials · 197 PubMed results

Promising

Research evidence

Melanotan II has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Melanotan II has 1 name-matched clinical trial (highest phase: Phase 2) and 197 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data

Phase 2

Trial quality

Randomized

Outcomes

Surrogate / early

Replication

Multiple papers

Literature

High-impact

PHASE2 · RandomizedMelanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo International Journal of Impotence Research · 118 citationsMelanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II European Journal of Pharmaceutics and Biopharmaceutics · 64 citationsNanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery Journal of Endocrinology · 56 citationsUnabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression Case ReportsChanges in Oral Mucosa Associated with Melanotan II Injections: A Case Report.Case ReportsMelanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What melanotan II is

Melanotan II is a melanocortin analogue that appears frequently in online tanning and cosmetic conversations. It is one of the better-known examples of a peptide with strong consumer curiosity but no FDA-approved status.

Why it matters

It helps define the difference between cosmetic-demand peptides and clinically grounded peptide therapies.

Regulatory context

Melanotan II is not FDA approved in the United States. It belongs in the research-market bucket.

Practical reading note

Because tanning-related demand can blur aesthetic goals and safety assumptions, this is a category where formal approval status matters a lot.